Cabergoline

Generic name: Pronounced as (ka ber' goe leen)
Brand names
  • Dostinex®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 02/15/2017

Cabergoline is used to treat hyperprolactinemia (high levels of prolactin, a natural substance that helps breast-feeding women produce milk but can cause symptoms such as infertility, sexual problems, and bone loss in women who are not breast-feeding or men). Cabergoline is in a class of medications called dopamine receptor agonists. It works by decreasing the amount of prolactin in the body.

Cabergoline comes as a tablet to take by mouth. It is usually taken with or without food two times a week. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take cabergoline exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor will probably start you on a low dose of cabergoline and gradually increase your dose, not more often than once every 4 weeks.

Do not stop taking cabergoline without talking to your doctor. Your doctor will probably decrease your dose gradually.

Cabergoline is also sometimes used to treat Parkinson's disease (a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Talk to your doctor about the risks of using this medication for your condition.

Before taking cabergoline,

  • tell your doctor and pharmacist if you are allergic to cabergoline, ergot medications such as bromocriptine (Parlodel); dihydroergotamine (D.H.E. 45, Migranal), ergoloid mesylates (Hydergine), ergotamine (in Cafergot, in Ergomar), methylergonovine (Methergine), methysergide (Sansert), and pergolide (Permax); any other medications, or any of the ingredients in cabergoline tablets. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antihistamines; ergot medications such as dihydroergotamine (D.H.E. 45, Migranal), ergotamine (in Cafergot, in Ergomar), and methylergonovine (Methergine); haloperidol (Haldol); levodopa (in Parcopa, Sinemet, and Stalevo); medications for high blood pressure, mental illness, or nausea; metoclopramide (Reglan); or thiothixene (Navane). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you use or have ever used street drugs and if you have or have ever had high blood pressure or any condition that causes thickening or scarring in your lungs, heart, or abdomen. Also tell your doctor if you have or have ever had heart valve disease. Your doctor will examine you and will order tests to see if your heart valves are healthy. Your doctor may tell you not to take cabergoline if you have signs of heart valve disease or any of these conditions.

  • tell your doctor if you have or have ever had liver disease.

  • tell your doctor if you are pregnant or plan to become pregnant. If you become pregnant while taking cabergoline, call your doctor.

  • tell your doctor if you are breast-feeding or plan to breast-feed. Cabergoline may slow or stop the production of breast-milk.

  • you should know that cabergoline may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common when you first start taking cabergoline. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

  • you should know that some people treated with cabergoline have developed gambling problems or other intense urges or behaviors that were compulsive or unusual for them, such as increased sexual urges or behaviors. There is not enough information to tell whether the people developed these problems because they took the medication or for other reasons. Call your doctor if you have an urge to gamble that is difficult to control, you have intense urges, or you are unable to control your behavior. Tell your family members about this risk so that they can call the doctor even if you do not realize that your gambling or any other intense urges or unusual behaviors have become a problem.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Cabergoline may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • vomiting

    • heartburn

    • constipation

    • tiredness

    • dizziness

    • breast pain

    • painful menstrual periods

    • burning, numbness, or tingling in the arms, hands, legs, or feet

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical help:

    • shortness of breath

    • difficulty breathing when lying down

    • cough

    • chest pain

    • swelling of the hands, feet, ankles, or lower legs

    • decrease in urination

    • pain in the back, side, or groin

    • lumps or pain in the stomach area

    • abnormal vision

  • Cabergoline may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • stuffy nose

  • fainting

  • hallucinations (seeing things or hearing voices that do not exist)

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests and other tests to check your body's response to cabergoline.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Delavirdine Delavirdine The metabolism of Cabergoline can be decreased when combined with Delavirdine.
Atorvastatin Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Cabergoline.
Dolasetron Dolasetron The risk or severity of adverse effects can be increased when Cabergoline is combined with Dolasetron.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Cabergoline.
Candesartan Candesartan Cabergoline may decrease the antihypertensive activities of Candesartan.
Cilostazol Cilostazol The metabolism of Cilostazol can be decreased when combined with Cabergoline.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Cabergoline is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole Erythromycin may increase the vasoconstricting activities of Cabergoline.
Fenofibrate Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Cabergoline.
Guanfacine Guanfacine Cabergoline may increase the hypertensive and vasoconstricting activities of Guanfacine.
Methylergonovine Methylergonovine The metabolism of Cabergoline can be decreased when combined with Methylergometrine.
Naratriptan Naratriptan Cabergoline may increase the vasoconstricting activities of Naratriptan.
Olsalazine Olsalazine The risk or severity of hypertension can be increased when Cabergoline is combined with Olsalazine.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Cabergoline is combined with Morphine.
Penbutolol Penbutolol Acebutolol may increase the vasoconstricting activities of Cabergoline.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Cabergoline is combined with Pentazocine.
Reserpine Reserpine The serum concentration of Reserpine can be increased when it is combined with Cabergoline.
Rizatriptan Rizatriptan Cabergoline may increase the vasoconstricting activities of Rizatriptan.
Sumatriptan Sumatriptan Cabergoline may increase the vasoconstricting activities of Sumatriptan.
Tacrolimus Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Cabergoline.
Tizanidine Tizanidine Cabergoline may increase the hypertensive and vasoconstricting activities of Tizanidine.
Triamcinolone Triamcinolone The metabolism of Cabergoline can be increased when combined with Triamcinolone.
Zolmitriptan Zolmitriptan The risk or severity of vasospastic reactions can be increased when Cabergoline is combined with Zolmitriptan.
Doxycycline Injection Doxycycline Injection The metabolism of Cabergoline can be decreased when combined with Doxycycline.
Fluconazole Injection Fluconazole Injection The metabolism of Cabergoline can be decreased when combined with Fluconazole.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Hydromorphone.
Meperidine Injection Meperidine Injection The metabolism of Meperidine can be increased when combined with Cabergoline.
Methylprednisolone Injection Methylprednisolone Injection The metabolism of Cabergoline can be increased when combined with Methylprednisolone.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Cabergoline.
Metronidazole Injection Metronidazole Injection The metabolism of Cabergoline can be decreased when combined with Metronidazole.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Morphine.
Altretamine Altretamine The metabolism of Cabergoline can be decreased when combined with Amphetamine.
Cyclosporine Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Cabergoline.
Ondansetron Ondansetron The risk or severity of adverse effects can be increased when Cabergoline is combined with Ondansetron.
Granisetron Granisetron The risk or severity of adverse effects can be increased when Cabergoline is combined with Granisetron.
Torsemide Torsemide Cabergoline may decrease the antihypertensive activities of Torasemide.
Olanzapine Olanzapine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Cabergoline is combined with Alosetron.
Dofetilide Dofetilide The metabolism of Dofetilide can be decreased when combined with Cabergoline.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Cabergoline is combined with Entacapone.
Eprosartan Eprosartan Cabergoline may decrease the antihypertensive activities of Eprosartan.
Meloxicam Meloxicam The risk or severity of hypertension can be increased when Cabergoline is combined with Meloxicam.
Orlistat Orlistat The metabolism of Cabergoline can be increased when combined with Orlistat.
Oxcarbazepine Oxcarbazepine The metabolism of Oxcarbazepine can be increased when combined with Cabergoline.
Telmisartan Telmisartan Cabergoline may decrease the antihypertensive activities of Telmisartan.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Cabergoline is combined with Zaleplon.
Anakinra Anakinra The metabolism of Cabergoline can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of adverse effects can be increased when Cabergoline is combined with Desloratadine.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Cabergoline.
Trimipramine Trimipramine The risk or severity of adverse effects can be increased when Cabergoline is combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Cabergoline can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil Modafinil The metabolism of Cabergoline can be increased when combined with Modafinil.
Perindopril Perindopril Cabergoline may decrease the antihypertensive activities of Perindopril.
Tenofovir Tenofovir The metabolism of Tenofovir can be decreased when combined with Cabergoline.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of hypertension can be increased when Cabergoline is combined with Choline magnesium trisalicylate.
Sirolimus Sirolimus The metabolism of Sirolimus can be decreased when combined with Cabergoline.
Dutasteride Dutasteride The risk or severity of hypertension can be increased when Cabergoline is combined with Dutasteride.
Epinephrine Injection Epinephrine Injection The metabolism of Epinephrine can be decreased when combined with Cabergoline.
Eplerenone Eplerenone Cabergoline may decrease the antihypertensive activities of Eplerenone.
Escitalopram Escitalopram The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Escitalopram.
Olmesartan Olmesartan Cabergoline may decrease the antihypertensive activities of Olmesartan.
Zonisamide Zonisamide The serum concentration of Zonisamide can be increased when it is combined with Cabergoline.
Adalimumab Injection Adalimumab Injection The metabolism of Cabergoline can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Cabergoline.
Atomoxetine Atomoxetine The risk or severity of adverse effects can be increased when Cabergoline is combined with Atomoxetine.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Cabergoline.
Atazanavir Atazanavir The metabolism of Atazanavir can be decreased when combined with Cabergoline.
Almotriptan Almotriptan Cabergoline may increase the vasoconstricting activities of Almotriptan.
Eletriptan Eletriptan Eletriptan may increase the vasoconstricting activities of Cabergoline.
Mefloquine Mefloquine The metabolism of Cabergoline can be decreased when combined with Mefloquine.
Rosuvastatin Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Cabergoline.
Vardenafil Vardenafil The metabolism of Vardenafil can be decreased when combined with Cabergoline.
Alfuzosin Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Cabergoline.
Aprepitant Aprepitant The metabolism of Cabergoline can be decreased when combined with Aprepitant.
Tegaserod Tegaserod The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Tegaserod.
Tadalafil Tadalafil Cabergoline may decrease the antihypertensive activities of Tadalafil.
Frovatriptan Frovatriptan Cabergoline may increase the vasoconstricting activities of Frovatriptan.
Progesterone Progesterone The metabolism of Cabergoline can be increased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be decreased when Cabergoline is combined with Apomorphine.
Darbepoetin Alfa Injection Darbepoetin Alfa Injection The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cabergoline.
Infliximab Injection Infliximab Injection The metabolism of Cabergoline can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of adverse effects can be increased when Cabergoline is combined with Protriptyline.
Rifaximin Rifaximin The metabolism of Cabergoline can be increased when combined with Rifaximin.
Duloxetine Duloxetine The metabolism of Duloxetine can be decreased when combined with Cabergoline.
Norethindrone Norethindrone The metabolism of Norethisterone can be decreased when combined with Cabergoline.
Trospium Trospium Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan Bosentan The metabolism of Bosentan can be increased when combined with Cabergoline.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Cabergoline.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Cabergoline is combined with Eszopiclone.
Solifenacin Solifenacin Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Voriconazole Voriconazole The metabolism of Cabergoline can be decreased when combined with Voriconazole.
Dextroamphetamine Dextroamphetamine The metabolism of Cabergoline can be decreased when combined with Amphetamine.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Isocarboxazid Isocarboxazid The metabolism of Cabergoline can be decreased when combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Cabergoline is combined with Ramelteon.
Darifenacin Darifenacin Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl The metabolism of Fentanyl can be decreased when combined with Cabergoline.
Pregabalin Pregabalin The therapeutic efficacy of Cabergoline can be increased when used in combination with Pregabalin.
Deferasirox Deferasirox The metabolism of Cabergoline can be increased when combined with Deferasirox.
Phenylephrine Phenylephrine Cabergoline may increase the hypertensive and vasoconstricting activities of Phenylephrine.
Tipranavir Tipranavir The metabolism of Cabergoline can be decreased when combined with Tipranavir.
Felbamate Felbamate The metabolism of Felbamate can be increased when combined with Cabergoline.
Ranolazine Ranolazine The metabolism of Cabergoline can be decreased when combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Cabergoline can be increased when combined with Abatacept.
Rasagiline Rasagiline The metabolism of Cabergoline can be decreased when combined with Rasagiline.
Imatinib Imatinib The metabolism of Imatinib can be decreased when combined with Cabergoline.
Sitagliptin Sitagliptin The serum concentration of Cabergoline can be increased when it is combined with Sitagliptin.
Gefitinib Gefitinib The metabolism of Cabergoline can be decreased when combined with Gefitinib.
Albuterol Albuterol Cabergoline may increase the hypertensive and vasoconstricting activities of Salbutamol.
Paliperidone Paliperidone The serum concentration of Paliperidone can be increased when it is combined with Cabergoline.
Bortezomib Bortezomib The metabolism of Bortezomib can be decreased when combined with Cabergoline.
Posaconazole Posaconazole The serum concentration of Cabergoline can be increased when it is combined with Posaconazole.
Primaquine Primaquine The metabolism of Cabergoline can be decreased when combined with Primaquine.
Aliskiren Aliskiren Cabergoline may decrease the antihypertensive activities of Aliskiren.
Darunavir Darunavir The serum concentration of Cabergoline can be increased when it is combined with Darunavir.
Dimenhydrinate Dimenhydrinate The risk or severity of adverse effects can be increased when Cabergoline is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Lisdexamfetamine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Retapamulin Retapamulin The metabolism of Retapamulin can be decreased when combined with Cabergoline.
Sorafenib Sorafenib The metabolism of Sorafenib can be decreased when combined with Cabergoline.
Sunitinib Sunitinib The metabolism of Sunitinib can be decreased when combined with Cabergoline.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Lapatinib Lapatinib The metabolism of Cabergoline can be decreased when combined with Lapatinib.
Levocetirizine Levocetirizine The risk or severity of adverse effects can be increased when Cabergoline is combined with Levocetirizine.
Dasatinib Dasatinib The metabolism of Dasatinib can be decreased when combined with Cabergoline.
Armodafinil Armodafinil The metabolism of Cabergoline can be increased when combined with Armodafinil.
Ivermectin Ivermectin The metabolism of Cabergoline can be increased when combined with Ivermectin.
Temsirolimus Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Cabergoline.
Nilotinib Nilotinib The metabolism of Cabergoline can be decreased when combined with Nilotinib.
Toremifene Toremifene The serum concentration of Cabergoline can be increased when it is combined with Toremifene.
Bexarotene Bexarotene The metabolism of Cabergoline can be increased when combined with Bexarotene.
Budesonide Budesonide The metabolism of Cabergoline can be increased when combined with Budesonide.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Cabergoline can be decreased when combined with Chloramphenicol.
Desmopressin Desmopressin The risk or severity of hypertension can be increased when Desmopressin is combined with Cabergoline.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cabergoline.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cabergoline.
Etravirine Etravirine The metabolism of Cabergoline can be increased when combined with Etravirine.
Mitoxantrone Injection Mitoxantrone Injection The metabolism of Cabergoline can be decreased when combined with Mitoxantrone.
Desvenlafaxine Desvenlafaxine The metabolism of Desvenlafaxine can be decreased when combined with Cabergoline.
Nebivolol Nebivolol Cabergoline may increase the hypertensive and vasoconstricting activities of Nebivolol.
Pilocarpine Pilocarpine The metabolism of Cabergoline can be decreased when combined with Pilocarpine.
Certolizumab Injection Certolizumab Injection The metabolism of Cabergoline can be increased when combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The metabolism of Cabergoline can be decreased when combined with Ixabepilone.
Irinotecan Injection Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Cabergoline.
Mitotane Mitotane The metabolism of Cabergoline can be increased when combined with Mitotane.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Cabergoline.
Silodosin Silodosin The serum concentration of Cabergoline can be increased when it is combined with Silodosin.
Midazolam Midazolam The serum concentration of Midazolam can be increased when it is combined with Cabergoline.
Naltrexone Injection Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Naltrexone.
Milnacipran Milnacipran The metabolism of Milnacipran can be decreased when combined with Cabergoline.
Fesoterodine Fesoterodine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Betaxolol Betaxolol Betaxolol may increase the vasoconstricting activities of Cabergoline.
Iloperidone Iloperidone The metabolism of Iloperidone can be decreased when combined with Cabergoline.
Lacosamide Lacosamide The metabolism of Lacosamide can be decreased when combined with Cabergoline.
Everolimus Everolimus The metabolism of Everolimus can be decreased when combined with Cabergoline.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The metabolism of Tolvaptan can be decreased when combined with Cabergoline.
Dronedarone Dronedarone The serum concentration of Dronedarone can be increased when it is combined with Cabergoline.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cabergoline.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Palonosetron.
Romidepsin Injection Romidepsin Injection The metabolism of Romidepsin can be decreased when combined with Cabergoline.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Topotecan Topotecan The metabolism of Cabergoline can be increased when combined with Topotecan.
Golimumab Injection Golimumab Injection The metabolism of Cabergoline can be increased when combined with Golimumab.
Pazopanib Pazopanib The metabolism of Cabergoline can be decreased when combined with Pazopanib.
Asenapine Asenapine The therapeutic efficacy of Cabergoline can be decreased when used in combination with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Cabergoline is combined with Vigabatrin.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Cabergoline.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Cabergoline is combined with Oxymorphone.
Tocilizumab Injection Tocilizumab Injection The metabolism of Cabergoline can be increased when combined with Tocilizumab.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cabergoline.
Cabazitaxel Injection Cabazitaxel Injection The metabolism of Cabergoline can be decreased when combined with Cabazitaxel.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection The metabolism of Cabergoline can be increased when combined with Acetaminophen.
Vilazodone Vilazodone Cabergoline may increase the vasoconstricting activities of Vilazodone.
Denileukin Diftitox Injection Denileukin Diftitox Injection The metabolism of Cabergoline can be decreased when combined with Aldesleukin.
Terbutaline Injection Terbutaline Injection Cabergoline may increase the hypertensive and vasoconstricting activities of Terbutaline.
Busulfan Injection Busulfan Injection The metabolism of Busulfan can be decreased when combined with Cabergoline.
Roflumilast Roflumilast The metabolism of Roflumilast can be decreased when combined with Cabergoline.
Linagliptin Linagliptin The metabolism of Linagliptin can be decreased when combined with Cabergoline.
Rilpivirine Rilpivirine The metabolism of Cabergoline can be decreased when combined with Rilpivirine.
Telaprevir Telaprevir The metabolism of Cabergoline can be decreased when combined with Glecaprevir.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Cabergoline can be increased when combined with Cyclophosphamide.
Rivaroxaban Rivaroxaban The serum concentration of Cabergoline can be increased when it is combined with Rivaroxaban.
Ticagrelor Ticagrelor The metabolism of Cabergoline can be decreased when combined with Ticagrelor.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The metabolism of Brentuximab vedotin can be decreased when combined with Cabergoline.
Ruxolitinib Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Cabergoline.
Vandetanib Vandetanib The metabolism of Vandetanib can be decreased when combined with Cabergoline.
Clobazam Clobazam The metabolism of Clobazam can be increased when combined with Cabergoline.
Vemurafenib Vemurafenib The metabolism of Vemurafenib can be decreased when combined with Cabergoline.
Ivacaftor Ivacaftor The metabolism of Cabergoline can be decreased when combined with Ivacaftor.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Cabergoline.
Crizotinib Crizotinib The metabolism of Cabergoline can be decreased when combined with Crizotinib.
Naloxone Injection Naloxone Injection The metabolism of Cabergoline can be decreased when combined with Naloxone.
Ambrisentan Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Cabergoline.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Cabergoline is combined with Tiagabine.
Carfilzomib Injection Carfilzomib Injection The serum concentration of Cabergoline can be increased when it is combined with Carfilzomib.
Enzalutamide Enzalutamide The metabolism of Cabergoline can be increased when combined with Enzalutamide.
Mirabegron Mirabegron The serum concentration of Mirabegron can be increased when it is combined with Cabergoline.
Regorafenib Regorafenib The metabolism of Cabergoline can be decreased when combined with Regorafenib.
Bosutinib Bosutinib The metabolism of Bosutinib can be decreased when combined with Cabergoline.
Corticotropin, Repository Injection Corticotropin, Repository Injection The metabolism of Cabergoline can be increased when combined with Corticotropin.
Tofacitinib Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Cabergoline.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Cabergoline.
Pomalidomide Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Cabergoline.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The metabolism of Cabergoline can be decreased when combined with Trastuzumab emtansine.
Apixaban Apixaban The serum concentration of Cabergoline can be increased when it is combined with Apixaban.
Canagliflozin Canagliflozin The serum concentration of Cabergoline can be increased when it is combined with Canagliflozin.
Dabrafenib Dabrafenib The metabolism of Cabergoline can be increased when combined with Dabrafenib.
Trametinib Trametinib The metabolism of Cabergoline can be increased when combined with Trametinib.
Dolutegravir Dolutegravir The serum concentration of Cabergoline can be increased when it is combined with Dolutegravir.
Afatinib Afatinib The serum concentration of Cabergoline can be increased when it is combined with Afatinib.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Cabergoline is combined with Levomilnacipran.
Vortioxetine Vortioxetine Cabergoline may increase the vasoconstricting activities of Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Cabergoline.
Lomitapide Lomitapide The metabolism of Lomitapide can be decreased when combined with Cabergoline.
Ketorolac Injection Ketorolac Injection The risk or severity of hypertension can be increased when Cabergoline is combined with Ketorolac.
Simeprevir Simeprevir The metabolism of Cabergoline can be decreased when combined with Simeprevir.
Sofosbuvir Sofosbuvir The serum concentration of Cabergoline can be increased when it is combined with Sofosbuvir.
Apremilast Apremilast The metabolism of Cabergoline can be increased when combined with Apremilast.
Droxidopa Droxidopa Cabergoline may increase the hypertensive activities of Droxidopa.
Ceritinib Ceritinib The metabolism of Ceritinib can be decreased when combined with Cabergoline.
Siltuximab Injection Siltuximab Injection The metabolism of Cabergoline can be increased when combined with Siltuximab.
Eslicarbazepine Eslicarbazepine The metabolism of Eslicarbazepine can be increased when combined with Cabergoline.
Belinostat Injection Belinostat Injection The serum concentration of Cabergoline can be increased when it is combined with Belinostat.
Idelalisib Idelalisib The metabolism of Idelalisib can be decreased when combined with Cabergoline.
Testosterone Injection Testosterone Injection The metabolism of Cabergoline can be increased when combined with Testosterone.
Oritavancin Injection Oritavancin Injection The metabolism of Cabergoline can be increased when combined with Oritavancin.
Vorapaxar Vorapaxar The serum concentration of Vorapaxar can be increased when it is combined with Cabergoline.
Hydrocodone Hydrocodone Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Edoxaban Edoxaban The serum concentration of Cabergoline can be increased when it is combined with Edoxaban.
Olaparib Olaparib The metabolism of Cabergoline can be decreased when combined with Olaparib.
Methamphetamine Methamphetamine Cabergoline may increase the hypertensive and vasoconstricting activities of Metamfetamine.
Tasimelteon Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Cabergoline.
Riociguat Riociguat Cabergoline may decrease the antihypertensive activities of Riociguat.
Lanreotide Injection Lanreotide Injection The metabolism of Cabergoline can be decreased when combined with Lanreotide.
Nintedanib Nintedanib The metabolism of Nintedanib can be decreased when combined with Cabergoline.
Secukinumab Injection Secukinumab Injection The metabolism of Cabergoline can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Risperidone.
Palbociclib Palbociclib The metabolism of Cabergoline can be decreased when combined with Palbociclib.
Lenvatinib Lenvatinib The metabolism of Cabergoline can be increased when combined with Lenvatinib.
Panobinostat Panobinostat The metabolism of Panobinostat can be decreased when combined with Cabergoline.
Haloperidol Injection Haloperidol Injection The risk or severity of CNS depression can be increased when Cabergoline is combined with Haloperidol.
Isavuconazonium Injection Isavuconazonium Injection The metabolism of Cabergoline can be increased when combined with Isavuconazonium.
Macitentan Macitentan Cabergoline may decrease the antihypertensive activities of Macitentan.
Sonidegib Sonidegib The metabolism of Sonidegib can be decreased when combined with Cabergoline.
Flibanserin Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Cabergoline.
Rolapitant Rolapitant The serum concentration of Cabergoline can be increased when it is combined with Rolapitant.
Prednisolone Prednisolone The metabolism of Cabergoline can be increased when combined with Prednisolone.
Daclatasvir Daclatasvir The serum concentration of Cabergoline can be increased when it is combined with Daclatasvir.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be decreased when Cabergoline is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Ziprasidone.
Cariprazine Cariprazine Cabergoline may increase the vasoconstricting activities of Cariprazine.
Eluxadoline Eluxadoline The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Eluxadoline.
Cobimetinib Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Cabergoline.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Cabergoline.
Osimertinib Osimertinib The metabolism of Osimertinib can be increased when combined with Cabergoline.
Alectinib Alectinib The metabolism of Alectinib can be decreased when combined with Cabergoline.
Ixazomib Ixazomib The metabolism of Ixazomib can be decreased when combined with Cabergoline.
Rifapentine Rifapentine The metabolism of Cabergoline can be increased when combined with Rifapentine.
Lesinurad Lesinurad The metabolism of Cabergoline can be increased when combined with Lesinurad.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection The metabolism of Cabergoline can be decreased when combined with Amphotericin B.
Dexamethasone Injection Dexamethasone Injection The metabolism of Cabergoline can be increased when combined with Dexamethasone.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Brivaracetam.
Venetoclax Venetoclax The metabolism of Venetoclax can be decreased when combined with Cabergoline.
Cobicistat Cobicistat The serum concentration of Cabergoline can be increased when it is combined with Cobicistat.
Midodrine Midodrine Cabergoline may increase the hypertensive and vasoconstricting activities of Midodrine.
Selexipag Selexipag The serum concentration of Selexipag can be increased when it is combined with Cabergoline.
Pimavanserin Pimavanserin The therapeutic efficacy of Cabergoline can be decreased when used in combination with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Diphenhydramine.
Furosemide Injection Furosemide Injection Cabergoline may decrease the antihypertensive activities of Furosemide.
Rucaparib Rucaparib The metabolism of Cabergoline can be decreased when combined with Rucaparib.
Ribociclib Ribociclib The metabolism of Ribociclib can be decreased when combined with Cabergoline.
Brigatinib Brigatinib The metabolism of Cabergoline can be increased when combined with Brigatinib.
Doxepin (Insomnia) Doxepin (Insomnia) Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Deflazacort Deflazacort The metabolism of Cabergoline can be increased when combined with Deflazacort.
Safinamide Safinamide The metabolism of Cabergoline can be decreased when combined with Safinamide.
Sarilumab Injection Sarilumab Injection The metabolism of Cabergoline can be increased when combined with Sarilumab.
Midostaurin Midostaurin The metabolism of Cabergoline can be increased when combined with Midostaurin.
Neratinib Neratinib The metabolism of Neratinib can be decreased when combined with Cabergoline.
Enasidenib Enasidenib The metabolism of Enasidenib can be decreased when combined with Cabergoline.
Inotuzumab Ozogamicin Injection Inotuzumab Ozogamicin Injection The serum concentration of Cabergoline can be increased when it is combined with Inotuzumab ozogamicin.
Aprepitant/Fosaprepitant Injection Aprepitant/Fosaprepitant Injection The metabolism of Fosaprepitant can be increased when combined with Cabergoline.
Copanlisib Injection Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Cabergoline.
Abemaciclib Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Cabergoline.
Betrixaban Betrixaban The serum concentration of Cabergoline can be increased when it is combined with Betrixaban.
Acalabrutinib Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Cabergoline.
Letermovir Letermovir The metabolism of Cabergoline can be decreased when combined with Letermovir.
Ertugliflozin Ertugliflozin The serum concentration of Cabergoline can be increased when it is combined with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The metabolism of Cabergoline can be increased when combined with Apalutamide.
Fostamatinib Fostamatinib The metabolism of Cabergoline can be decreased when combined with Fostamatinib.
Avatrombopag Avatrombopag The serum concentration of Cabergoline can be increased when it is combined with Avatrombopag.
Baricitinib Baricitinib The metabolism of Baricitinib can be decreased when combined with Cabergoline.
Lofexidine Lofexidine The therapeutic efficacy of Cabergoline can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The metabolism of Eliglustat can be decreased when combined with Cabergoline.
Ivosidenib Ivosidenib The metabolism of Cabergoline can be increased when combined with Ivosidenib.
Lusutrombopag Lusutrombopag The serum concentration of Cabergoline can be increased when it is combined with Lusutrombopag.
Elagolix Elagolix The serum concentration of Cabergoline can be increased when it is combined with Elagolix.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Cabergoline.
Dacomitinib Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Cabergoline.
Duvelisib Duvelisib The metabolism of Duvelisib can be decreased when combined with Cabergoline.
Omadacycline Omadacycline The serum concentration of Cabergoline can be increased when it is combined with Omadacycline.
Sarecycline Sarecycline The serum concentration of Cabergoline can be increased when it is combined with Sarecycline.
Stiripentol Stiripentol The metabolism of Stiripentol can be decreased when combined with Cabergoline.
Talazoparib Talazoparib The serum concentration of Cabergoline can be increased when it is combined with Talazoparib.
Gilteritinib Gilteritinib The therapeutic efficacy of Cabergoline can be decreased when used in combination with Gilteritinib.
Glasdegib Glasdegib The serum concentration of Cabergoline can be increased when it is combined with Glasdegib.
Larotrectinib Larotrectinib The serum concentration of Cabergoline can be increased when it is combined with Larotrectinib.
Methoxy Polyethylene Glycol-Epoetin Beta Injection Methoxy Polyethylene Glycol-Epoetin Beta Injection The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabergoline.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Cabergoline.
Rifamycin Rifamycin The metabolism of Cabergoline can be increased when combined with Rifamycin.
Prucalopride Prucalopride The metabolism of Prucalopride can be decreased when combined with Cabergoline.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Cabergoline can be increased when combined with Emapalumab.
Siponimod Siponimod The metabolism of Siponimod can be decreased when combined with Cabergoline.
Erdafitinib Erdafitinib The serum concentration of Erdafitinib can be increased when it is combined with Cabergoline.
Alpelisib Alpelisib The metabolism of Alpelisib can be decreased when combined with Cabergoline.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Cabergoline.
Darolutamide Darolutamide The serum concentration of Cabergoline can be increased when it is combined with Darolutamide.
Triclabendazole Triclabendazole The metabolism of Cabergoline can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The metabolism of Entrectinib can be decreased when combined with Cabergoline.
Pexidartinib Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Cabergoline.
Istradefylline Istradefylline The serum concentration of Cabergoline can be increased when it is combined with Istradefylline.
Pitolisant Pitolisant The serum concentration of Cabergoline can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The serum concentration of Cabergoline can be increased when it is combined with Fedratinib.
Lefamulin Lefamulin The serum concentration of Lefamulin can be increased when it is combined with Cabergoline.
Phenytoin Injection Phenytoin Injection The metabolism of Phenytoin can be increased when combined with Cabergoline.
Fosphenytoin Injection Fosphenytoin Injection The metabolism of Fosphenytoin can be decreased when combined with Cabergoline.
Enfortumab vedotin-ejfv Injection Enfortumab vedotin-ejfv Injection The serum concentration of Cabergoline can be increased when it is combined with Enfortumab vedotin.
Zanubrutinib Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Cabergoline.
Voxelotor Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Cabergoline.
Lumateperone Lumateperone The therapeutic efficacy of Cabergoline can be decreased when used in combination with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Cabergoline can be increased when it is combined with Ubrogepant.
Tazemetostat Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Cabergoline.
Cenobamate Cenobamate The serum concentration of Cabergoline can be decreased when it is combined with Cenobamate.
Selumetinib Selumetinib The serum concentration of Cabergoline can be increased when it is combined with Selumetinib.
Rimegepant Rimegepant The serum concentration of Cabergoline can be increased when it is combined with Rimegepant.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Cabergoline.
Remdesivir Injection Remdesivir Injection The serum concentration of Cabergoline can be increased when it is combined with Remdesivir.
Ripretinib Ripretinib The serum concentration of Cabergoline can be increased when it is combined with Ripretinib.
Selpercatinib Selpercatinib The risk or severity of hypertension can be increased when Cabergoline is combined with Selpercatinib.
Capmatinib Capmatinib The serum concentration of Cabergoline can be increased when it is combined with Capmatinib.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Cabergoline is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Fenfluramine.
Fostemsavir Fostemsavir The serum concentration of Cabergoline can be increased when it is combined with Fostemsavir.
Octreotide Octreotide The serum concentration of Cabergoline can be increased when it is combined with Octreotide.
Belantamab Mafodotin-blmf Injection Belantamab Mafodotin-blmf Injection The serum concentration of Cabergoline can be increased when it is combined with Belantamab mafodotin.
Pralsetinib Pralsetinib The metabolism of Cabergoline can be increased when combined with Pralsetinib.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Cabergoline can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Cabergoline is combined with Naxitamab.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Drospirenone can be decreased when combined with Cabergoline.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Cabergoline is combined with Viloxazine.
Vitamin E (Alpha-Tocopherol) Vitamin E (Alpha-Tocopherol) The metabolism of Cabergoline can be increased when combined with Vitamin E.
Theophylline Theophylline The metabolism of Theophylline can be decreased when combined with Cabergoline.
Fenoprofen Fenoprofen The risk or severity of hypertension can be increased when Cabergoline is combined with Fenoprofen.
Indomethacin Indomethacin The risk or severity of hypertension can be increased when Cabergoline is combined with Indomethacin.
Mefenamic Acid Mefenamic Acid The risk or severity of hypertension can be increased when Cabergoline is combined with Mefenamic acid.
Naproxen Naproxen The risk or severity of hypertension can be increased when Cabergoline is combined with Naproxen.
Tolmetin Tolmetin The risk or severity of hypertension can be increased when Cabergoline is combined with Tolmetin.
Sulindac Sulindac The risk or severity of hypertension can be increased when Cabergoline is combined with Sulindac.
Trazodone Trazodone The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Cabergoline.
Phenobarbital Phenobarbital The metabolism of Phenobarbital can be increased when combined with Cabergoline.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Cabergoline is combined with Metaxalone.
Methotrexate Injection Methotrexate Injection The metabolism of Methotrexate can be decreased when combined with Cabergoline.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Cabergoline is combined with Levorphanol.
Primidone Primidone The metabolism of Primidone can be increased when combined with Cabergoline.
Methsuximide Methsuximide The risk or severity of adverse effects can be increased when Cabergoline is combined with Methsuximide.
Diethylpropion Diethylpropion The risk or severity of adverse effects can be increased when Cabergoline is combined with Diethylpropion.
Chlorpromazine Chlorpromazine The therapeutic efficacy of Cabergoline can be decreased when used in combination with Chlorpromazine.
Diazepam Diazepam The metabolism of Diazepam can be decreased when combined with Cabergoline.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Cabergoline is combined with Oxazepam.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Cabergoline is combined with Flurazepam.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Cabergoline is combined with Clorazepic acid.
Lorazepam Lorazepam The metabolism of Cabergoline can be decreased when combined with Lorazepam.
Phenoxybenzamine Phenoxybenzamine The risk or severity of hypertension can be increased when Cabergoline is combined with Phenoxybenzamine.
Amantadine Amantadine The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Amantadine.
Codeine Codeine The risk or severity of adverse effects can be increased when Cabergoline is combined with Codeine.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Cabergoline is combined with Meprobamate.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Cabergoline is combined with Chlordiazepoxide.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be decreased when Cabergoline is combined with Bromocriptine.
Metaproterenol Metaproterenol Cabergoline may increase the hypertensive and vasoconstricting activities of Orciprenaline.
Tranylcypromine Tranylcypromine The metabolism of Cabergoline can be decreased when combined with Tranylcypromine.
Phenelzine Phenelzine The metabolism of Cabergoline can be decreased when combined with Phenelzine.
Procarbazine Procarbazine The metabolism of Cabergoline can be decreased when combined with Procarbazine.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be decreased when Cabergoline is combined with Ergoloid mesylate.
Tetracycline Tetracycline The metabolism of Cabergoline can be decreased when combined with Tetracycline.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Prochlorperazine Prochlorperazine The therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Cabergoline.
Thioridazine Thioridazine The therapeutic efficacy of Cabergoline can be decreased when used in combination with Thioridazine.
Trifluoperazine Trifluoperazine The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Cabergoline.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Cabergoline is combined with Oxycodone.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Cabergoline.
Oxybutynin Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Cabergoline.
Benztropine Benztropine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Maprotiline Maprotiline The risk or severity of adverse effects can be increased when Cabergoline is combined with Maprotiline.
Ibuprofen Ibuprofen The risk or severity of hypertension can be increased when Cabergoline is combined with Ibuprofen.
Trihexyphenidyl Trihexyphenidyl Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The therapeutic efficacy of Perphenazine can be decreased when used in combination with Cabergoline.
Fluphenazine Fluphenazine The therapeutic efficacy of Fluphenazine can be decreased when used in combination with Cabergoline.
Phentermine Phentermine The metabolism of Cabergoline can be decreased when combined with Phentermine.
Methylphenidate Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Cabergoline.
Amoxapine Amoxapine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
Sulfasalazine Sulfasalazine The risk or severity of hypertension can be increased when Cabergoline is combined with Sulfasalazine.
Hydrocortisone Hydrocortisone The metabolism of Cabergoline can be increased when combined with Hydrocortisone.
Doxorubicin Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Cabergoline.
Dactinomycin Dactinomycin The serum concentration of Cabergoline can be increased when it is combined with Dactinomycin.
Carbamazepine Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Cabergoline.
Molindone Molindone The therapeutic efficacy of Molindone can be decreased when used in combination with Cabergoline.
Methyldopa Methyldopa Cabergoline may increase the hypertensive and vasoconstricting activities of Methyldopa.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Cabergoline.
Prazosin Prazosin Cabergoline may decrease the antihypertensive activities of Prazosin.
Hydralazine Hydralazine The metabolism of Hydralazine can be decreased when combined with Cabergoline.
Cimetidine Cimetidine The metabolism of Cabergoline can be decreased when combined with Cimetidine.
Warfarin Warfarin The serum concentration of Warfarin can be increased when it is combined with Cabergoline.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Cabergoline is combined with Clonazepam.
Loperamide Loperamide The metabolism of Cabergoline can be decreased when combined with Loperamide.
Promethazine Promethazine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
Meclofenamate Meclofenamate The risk or severity of hypertension can be increased when Cabergoline is combined with Meclofenamic acid.
Daunorubicin Daunorubicin The metabolism of Daunorubicin can be decreased when combined with Cabergoline.
Griseofulvin Griseofulvin The metabolism of Cabergoline can be increased when combined with Griseofulvin.
Digoxin Digoxin The serum concentration of Cabergoline can be increased when it is combined with Digoxin.
Loxapine Loxapine The therapeutic efficacy of Cabergoline can be decreased when used in combination with Loxapine.
Quinine Quinine The metabolism of Quinine can be increased when combined with Cabergoline.
Ethosuximide Ethosuximide The risk or severity of adverse effects can be increased when Cabergoline is combined with Ethosuximide.
Calcitriol Calcitriol The metabolism of Cabergoline can be increased when combined with Calcitriol.
Sulfinpyrazone Sulfinpyrazone The metabolism of Cabergoline can be increased when combined with Sulfinpyrazone.
Chlorothiazide Chlorothiazide Cabergoline may decrease the antihypertensive activities of Chlorothiazide.
Chlorthalidone Chlorthalidone Cabergoline may decrease the antihypertensive activities of Chlorthalidone.
Metolazone Metolazone Cabergoline may decrease the antihypertensive activities of Metolazone.
Clindamycin Injection Clindamycin Injection The serum concentration of Cabergoline can be increased when it is combined with Clindamycin.
Secobarbital Secobarbital The metabolism of Secobarbital can be increased when combined with Cabergoline.
Desipramine Desipramine The metabolism of Desipramine can be decreased when combined with Cabergoline.
Amitriptyline Amitriptyline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
Imipramine Imipramine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Probenecid Probenecid The metabolism of Cabergoline can be increased when combined with Probenecid.
Quinidine Quinidine The metabolism of Quinidine can be decreased when combined with Cabergoline.
Isoniazid Isoniazid The metabolism of Isoniazid can be decreased when combined with Cabergoline.
Rifampin Rifampin The metabolism of Cabergoline can be increased when combined with Rifampicin.
Disopyramide Disopyramide Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Valproic Acid Valproic Acid The metabolism of Valproic acid can be decreased when combined with Cabergoline.
Tamoxifen Tamoxifen The metabolism of Cabergoline can be increased when combined with Tamoxifen.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Cabergoline.
Levothyroxine Levothyroxine The serum concentration of Cabergoline can be decreased when it is combined with Levothyroxine.
Methimazole Methimazole The metabolism of Cabergoline can be decreased when combined with Methimazole.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Cabergoline is combined with Dextromethorphan.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Cabergoline is combined with Cyclobenzaprine.
Niacin Niacin The metabolism of Cabergoline can be decreased when combined with Niacin.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Cabergoline.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Cyproheptadine Cyproheptadine The risk or severity of adverse effects can be increased when Cabergoline is combined with Cyproheptadine.
Clemastine Clemastine The risk or severity of adverse effects can be increased when Cabergoline is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of adverse effects can be increased when Cabergoline is combined with Dexbrompheniramine.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Cabergoline is combined with Meclizine.
Hydrochlorothiazide Hydrochlorothiazide Cabergoline may decrease the antihypertensive activities of Hydrochlorothiazide.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Cabergoline is combined with Dantrolene.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorzoxazone.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Cabergoline.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Cabergoline is combined with Methocarbamol.
Danazol Danazol The metabolism of Cabergoline can be decreased when combined with Danazol.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) Propranolol may increase the vasoconstricting activities of Cabergoline.
Minoxidil Minoxidil Cabergoline may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine Pseudoephedrine Cabergoline may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.
Nortriptyline Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Cabergoline.
Amphotericin B Injection Amphotericin B Injection The metabolism of Cabergoline can be decreased when combined with Amphotericin B.
Nadolol Nadolol Nadolol may increase the vasoconstricting activities of Cabergoline.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Butorphanol.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Cabergoline is combined with Nalbuphine.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Cabergoline is combined with Trimethobenzamide.
Clomiphene Clomiphene The serum concentration of Cabergoline can be increased when it is combined with Clomifene.
Flavoxate Flavoxate Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Colchicine Colchicine The metabolism of Colchicine can be decreased when combined with Cabergoline.
Cephalexin Cephalexin The metabolism of Cephalexin can be decreased when combined with Cabergoline.
Acetazolamide Acetazolamide The metabolism of Acetazolamide can be decreased when combined with Cabergoline.
Ketoconazole Ketoconazole The metabolism of Cabergoline can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Cabergoline is combined with Pyrantel.
Thiotepa Injection Thiotepa Injection The metabolism of Thiotepa can be decreased when combined with Cabergoline.
Vincristine Injection Vincristine Injection The metabolism of Vincristine can be decreased when combined with Cabergoline.
Captopril Captopril Cabergoline may decrease the antihypertensive activities of Captopril.
Isoxsuprine Isoxsuprine Cabergoline may increase the hypertensive and vasoconstricting activities of Isoxsuprine.
Vinblastine Vinblastine The metabolism of Vinblastine can be decreased when combined with Cabergoline.
Metoprolol Metoprolol The metabolism of Cabergoline can be decreased when combined with Metoprolol.
Hydroxyzine Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.
Thiothixene Thiothixene The therapeutic efficacy of Thiothixene can be decreased when used in combination with Cabergoline.
Aspirin Aspirin The risk or severity of hypertension can be increased when Cabergoline is combined with Acetylsalicylic acid.
Salsalate Salsalate The risk or severity of hypertension can be increased when Cabergoline is combined with Salsalate.
Alprazolam Alprazolam The metabolism of Alprazolam can be decreased when combined with Cabergoline.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Cabergoline.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Cabergoline is combined with Triazolam.
Dicyclomine Dicyclomine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline Propantheline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem Diltiazem The metabolism of Diltiazem can be decreased when combined with Cabergoline.
Nifedipine Nifedipine The metabolism of Cabergoline can be increased when combined with Nifedipine.
Timolol Timolol Timolol may increase the vasoconstricting activities of Cabergoline.
Verapamil Verapamil The metabolism of Cabergoline can be decreased when combined with Verapamil.
Atenolol Atenolol Atenolol may increase the vasoconstricting activities of Cabergoline.
Pindolol Pindolol Pindolol may increase the vasoconstricting activities of Cabergoline.
Diflunisal Diflunisal The risk or severity of hypertension can be increased when Cabergoline is combined with Diflunisal.
Piroxicam Piroxicam The risk or severity of hypertension can be increased when Cabergoline is combined with Piroxicam.
Etoposide Etoposide The metabolism of Cabergoline can be increased when combined with Etoposide.
Glyburide Glyburide The metabolism of Cabergoline can be decreased when combined with Glyburide.
Indapamide Indapamide Cabergoline may decrease the antihypertensive activities of Indapamide.
Dicloxacillin Dicloxacillin The metabolism of Cabergoline can be increased when combined with Dicloxacillin.
Nafcillin Injection Nafcillin Injection The metabolism of Cabergoline can be increased when combined with Nafcillin.
Labetalol Labetalol Labetalol may increase the vasoconstricting activities of Cabergoline.
Guanabenz Guanabenz Cabergoline may increase the hypertensive and vasoconstricting activities of Guanabenz.
Ketoprofen Ketoprofen The risk or severity of hypertension can be increased when Cabergoline is combined with Ketoprofen.
Pimozide Pimozide The therapeutic efficacy of Pimozide can be decreased when used in combination with Cabergoline.
Enalapril Enalapril Cabergoline may decrease the antihypertensive activities of Enalapril.
Flurbiprofen Flurbiprofen The risk or severity of hypertension can be increased when Cabergoline is combined with Flurbiprofen.
Amiodarone Amiodarone The metabolism of Amiodarone can be decreased when combined with Cabergoline.
Buspirone Buspirone The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Buspirone.
Lovastatin Lovastatin The metabolism of Lovastatin can be decreased when combined with Cabergoline.
Ciprofloxacin Ciprofloxacin The metabolism of Cabergoline can be decreased when combined with Ciprofloxacin.
Mesalamine Mesalamine The risk or severity of hypertension can be increased when Mesalazine is combined with Cabergoline.
Diclofenac Diclofenac The risk or severity of hypertension can be increased when Cabergoline is combined with Diclofenac.
Fluoxetine Fluoxetine The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Fluoxetine.
Nimodipine Nimodipine Cabergoline may decrease the antihypertensive activities of Nimodipine.
Clozapine Clozapine The metabolism of Clozapine can be increased when combined with Cabergoline.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Cabergoline is combined with Estazolam.
Clarithromycin Clarithromycin The serum concentration of Cabergoline can be increased when it is combined with Clarithromycin.
Benazepril Benazepril Cabergoline may decrease the antihypertensive activities of Benazepril.
Etodolac Etodolac The risk or severity of hypertension can be increased when Cabergoline is combined with Etodolac.
Felodipine Felodipine The metabolism of Felodipine can be decreased when combined with Cabergoline.
Fosinopril Fosinopril Cabergoline may decrease the antihypertensive activities of Fosinopril.
Nabumetone Nabumetone The risk or severity of hypertension can be increased when Cabergoline is combined with Nabumetone.
Pravastatin Pravastatin The serum concentration of Cabergoline can be increased when it is combined with Pravastatin.
Quinapril Quinapril Cabergoline may decrease the antihypertensive activities of Quinapril.
Ramipril Ramipril Cabergoline may decrease the antihypertensive activities of Ramipril.
Simvastatin Simvastatin The serum concentration of Cabergoline can be increased when it is combined with Simvastatin.
Epoetin Alfa, Injection Epoetin Alfa, Injection The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cabergoline.
Amlodipine Amlodipine Cabergoline may decrease the antihypertensive activities of Amlodipine.
Teniposide Injection Teniposide Injection The metabolism of Teniposide can be decreased when combined with Cabergoline.
Itraconazole Itraconazole The metabolism of Cabergoline can be decreased when combined with Itraconazole.
Lisinopril Lisinopril Cabergoline may decrease the antihypertensive activities of Lisinopril.
Oxaprozin Oxaprozin The risk or severity of hypertension can be increased when Cabergoline is combined with Oxaprozin.
Rifabutin Rifabutin The metabolism of Cabergoline can be increased when combined with Rifabutin.
Sotalol Sotalol Sotalol may increase the vasoconstricting activities of Cabergoline.
Bisoprolol Bisoprolol Bisoprolol may increase the vasoconstricting activities of Cabergoline.
Zolpidem Zolpidem Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The metabolism of Doxazosin can be decreased when combined with Cabergoline.
Terazosin Terazosin Cabergoline may decrease the antihypertensive activities of Terazosin.
Isradipine Isradipine The metabolism of Isradipine can be decreased when combined with Cabergoline.
Omeprazole Omeprazole The metabolism of Cabergoline can be increased when combined with Omeprazole.
Cisapride Cisapride The metabolism of Cabergoline can be decreased when combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Cabergoline is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Cabergoline can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Venlafaxine.
Famciclovir Famciclovir The metabolism of Famciclovir can be decreased when combined with Cabergoline.
Fluvoxamine Fluvoxamine The metabolism of Cabergoline can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The metabolism of Cabergoline can be decreased when combined with Nefazodone.
Lamotrigine Lamotrigine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
Losartan Losartan The metabolism of Losartan can be decreased when combined with Cabergoline.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Cabergoline.
Vinorelbine Injection Vinorelbine Injection The metabolism of Vinorelbine can be decreased when combined with Cabergoline.
Moexipril Moexipril Cabergoline may decrease the antihypertensive activities of Moexipril.
Lansoprazole Lansoprazole The metabolism of Cabergoline can be increased when combined with Lansoprazole.
Ifosfamide Injection Ifosfamide Injection The metabolism of Cabergoline can be increased when combined with Ifosfamide.
Nicardipine Nicardipine The metabolism of Nicardipine can be decreased when combined with Cabergoline.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Cabergoline.
Ticlopidine Ticlopidine The metabolism of Ticlopidine can be decreased when combined with Cabergoline.
Saquinavir Saquinavir The metabolism of Cabergoline can be decreased when combined with Saquinavir.
Nisoldipine Nisoldipine Cabergoline may decrease the antihypertensive activities of Nisoldipine.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Cabergoline is combined with Riluzole.
Gemcitabine Injection Gemcitabine Injection The serum concentration of Cabergoline can be increased when it is combined with Gemcitabine.
Ritonavir Ritonavir The serum concentration of Cabergoline can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Cabergoline.
Clomipramine Clomipramine The metabolism of Clomipramine can be decreased when combined with Cabergoline.
Zafirlukast Zafirlukast The metabolism of Cabergoline can be decreased when combined with Zafirlukast.
Mirtazapine Mirtazapine Cabergoline may increase the serotonergic activities of Mirtazapine.
Trandolapril Trandolapril Cabergoline may decrease the antihypertensive activities of Trandolapril.
Topiramate Topiramate The metabolism of Topiramate can be increased when combined with Cabergoline.
Valsartan Valsartan Cabergoline may decrease the antihypertensive activities of Valsartan.
Pramipexole Pramipexole Cabergoline may increase the sedative activities of Pramipexole.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Cabergoline is combined with Donepezil.
Fexofenadine Fexofenadine The serum concentration of Cabergoline can be increased when it is combined with Fexofenadine.
Azithromycin Azithromycin The serum concentration of Cabergoline can be increased when it is combined with Azithromycin.
Carvedilol Carvedilol The serum concentration of Cabergoline can be increased when it is combined with Carvedilol.
Selegiline Selegiline The metabolism of Cabergoline can be decreased when combined with Selegiline.
Bicalutamide Bicalutamide The metabolism of Cabergoline can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Cabergoline is combined with Sertraline.
Propafenone Propafenone The serum concentration of Cabergoline can be increased when it is combined with Propafenone.
Raloxifene Raloxifene The metabolism of Cabergoline can be decreased when combined with Raloxifene.
Irbesartan Irbesartan The metabolism of Irbesartan can be decreased when combined with Cabergoline.
Ropinirole Ropinirole Cabergoline may increase the sedative activities of Ropinirole.
Finasteride Finasteride The risk or severity of hypertension can be increased when Cabergoline is combined with Finasteride.
Quetiapine Quetiapine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
Cetirizine Cetirizine The risk or severity of adverse effects can be increased when Cabergoline is combined with Cetirizine.
Paroxetine Paroxetine The metabolism of Paroxetine can be decreased when combined with Cabergoline.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Cabergoline is combined with Tolcapone.
Citalopram Citalopram The metabolism of Cabergoline can be decreased when combined with Citalopram.
Efavirenz Efavirenz The metabolism of Efavirenz can be increased when combined with Cabergoline.
Sildenafil Sildenafil The serum concentration of Cabergoline can be increased when it is combined with Sildenafil.
Celecoxib Celecoxib The risk or severity of hypertension can be increased when Cabergoline is combined with Celecoxib.
Tolterodine Tolterodine Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide Thalidomide Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide Balsalazide The risk or severity of hypertension can be increased when Cabergoline is combined with Balsalazide.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Cabergoline is combined with Levetiracetam.
Rabeprazole Rabeprazole The metabolism of Cabergoline can be decreased when combined with Rabeprazole.
Terbinafine Terbinafine The metabolism of Cabergoline can be increased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists